- Home
- GAIN vs TRDA Comparison
GAIN vs TRDA Comparison
Compare GAIN & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GAIN
- TRDA
- Stock Information
- Founded
- GAIN 2005
- TRDA 2016
- Country
- GAIN United States
- TRDA United States
- Employees
- GAIN N/A
- TRDA N/A
- Industry
- GAIN Finance: Consumer Services
- TRDA Biotechnology: Pharmaceutical Preparations
- Sector
- GAIN Finance
- TRDA Health Care
- Exchange
- GAIN Nasdaq
- TRDA Nasdaq
- Market Cap
- GAIN 481.7M
- TRDA 548.2M
- IPO Year
- GAIN 2005
- TRDA 2021
- Fundamental
- Price
- GAIN $13.25
- TRDA $12.64
- Analyst Decision
- GAIN Hold
- TRDA Strong Buy
- Analyst Count
- GAIN 2
- TRDA 3
- Target Price
- GAIN $13.75
- TRDA $25.67
- AVG Volume (30 Days)
- GAIN 132.8K
- TRDA 128.3K
- Earning Date
- GAIN 02-12-2025
- TRDA 03-12-2025
- Dividend Yield
- GAIN 7.25%
- TRDA N/A
- EPS Growth
- GAIN N/A
- TRDA N/A
- EPS
- GAIN 1.06
- TRDA 1.55
- Revenue
- GAIN $91,472,000.00
- TRDA $215,232,000.00
- Revenue This Year
- GAIN $5.77
- TRDA $47.45
- Revenue Next Year
- GAIN $3.37
- TRDA N/A
- P/E Ratio
- GAIN $12.50
- TRDA $8.18
- Revenue Growth
- GAIN 11.51
- TRDA 146.92
- 52 Week Low
- GAIN $12.46
- TRDA $11.35
- 52 Week High
- GAIN $14.85
- TRDA $21.79
- Technical
- Relative Strength Index (RSI)
- GAIN 51.41
- TRDA 24.83
- Support Level
- GAIN $12.54
- TRDA $12.02
- Resistance Level
- GAIN $13.05
- TRDA $18.76
- Average True Range (ATR)
- GAIN 0.22
- TRDA 0.92
- MACD
- GAIN 0.03
- TRDA -0.51
- Stochastic Oscillator
- GAIN 82.56
- TRDA 9.35
About GAIN Gladstone Investment Corporation Business Development Company
Gladstone Investment Corp operates as an externally managed, closed-end, non-diversified management investment company. Its objective is to invest in debt and equity securities of established private businesses operating in the U.S. and to (i) achieve and grow current income by investing in debt securities of established businesses. (ii) provide our stockholders with long-term capital appreciation in the value of our assets by investing in equity securities of established businesses. It focuses on investing in lower-middle-market private businesses.
About TRDA Entrada Therapeutics Inc.
Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.